Endomag is a medical technology company devoted to improving breast cancer care through its magnetic sensing technologies.
Endomag is a medical technology company devoted to improving the global standard of cancer care. The company's Sentimag probe, Magseed marker, and Magtrac node marker are already in use by many of the world’s leading physicians and cancer centers. Endomag's goal is to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is. As of 2019, the company has already helped 70,000+ women around the world access more precise and less invasive breast cancer care.Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), Endomag continues to develop its unique clinical platform from its headquarters in Cambridge, United Kingdom. The company sells its products through a network of distributors in Europe, the Middle East, Africa, and Australasia.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 30, 2020 | Series D | £15M | 1 | Molten Ventures | — | Detail |
Jul 23, 2018 | Series C | £8M | 1 | Molten Ventures | — | Detail |
Aug 13, 2013 | Series B | £2.10M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Molten Ventures | Yes | Series D |
Sarum Partners | — | Series B |